| Primary information |
|---|
| ID | antitb_1388, |
| Name | 21482189 |
| N-Terminal modification | Hepcidin |
| C-Terminal Modification | DTHFPICIFCCGCCHRSKCGMCCKT |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage between cys7-23, cys10-13, cys11-19,cys14-22 |
| Chirality | Cyclic |
| Nature | 25 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Human alveolar type 2 epithilium |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium H37Rv |
| Inhibition Concentration | in vivo |
| Sequence | 2011 |
| Cytotoxicity | A549 cell line |
| In vivo Model | NA |
| Lethal Dose | No cytotoxicity |
| Immune Responce | BALB/C |
| Mechanism of Action | NA |
| Target | Increased production of TNF-α, IL-1α |
| Combination Therapy | NA |
| Other activities | Mycobacterium tuberculosis + IFN-Î¥ |
| PMID | |
| Year of Publication | antimicrobial |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1544, |
| Name | 25613372 |
| N-Terminal modification | Hepcidin |
| C-Terminal Modification | DTHFPICIFCCGCCHRSKCGMCCKT |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 25 |
| Source | L |
| Origin | Cationic |
| Species | Protein derived |
| Strain | Derived from Hepcidin protein |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | induce expression of IFN-γ |
| Combination Therapy | Cause structural damage to mycobacteria |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |